The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

BENGALURU: At a global cell therapy symposium in the city, oncologists said India offers CAR-T cell therapy at one-tenth the ...

Remove this text and use the embed button to add an image. Although still in early clinical trials, if successful, E-SYNC could one day become the first CAR-T therapy to treat the aggressive brain ...

— WU-CART-007 achieved 91% overall response rate in global Phase 1/2 trial, substantially outperforming current standard of care — — BLA filing targeted for 2027; therapy holds potential to be first ...

Researchers were perplexed when the Food and Drug Administration announced it was investigating whether CAR-T therapy, one of the most effective treatments for blood cancers, could cause lymphoma.

Contrary to a warning placed on labels for CART-T cancer therapies, use of these treatments does not appear to boost the odds for a secondary cancer later, a new study shows. Researchers at Memorial ...

New research shows that GD2 CAR-T cell therapy offers a potential cure for neuroblastoma, with some patients achieving long-term remission for over a decade—marking a major milestone in solid tumor ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...

CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Elouise Wrisper’s cancer journey began with persistent back pain. It was 2021, and the retired teacher, who was active in ...

Saint Louis University (SLU) Radiation Therapy students Leah Mann and Lauren Hass won first and second place, respectively, in the poster competition at the Chicago Area Radiation Therapy (CART) ...